Skip to main content

Table 2 Intervention characteristics

From: The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review

First author Type of HT Dose of HT Route of HT Duration of HTa-mean (range/SD)b
Challberg [33] ET, EPT and tibolone NS NS 3.4 (0.1-19)
Chapman [37] NS NS NS 6 (0.75-9)
Eisen [21] ET and EPT NS NS 3.85c (NS)
Finch [38] ET and EPT NS NS NS
Gabriel [28] ET and EPT NS NS 2.79 ± 3.22
Garcia [30] NS NS Systemic HT (60%) NS
Heiniger [29] NS NS NS NS
Johansen [36] ET, EPT and tibolone NS Systemic HT (39.28%) & local/vaginal HT (6.54%) NS
Kotsopoulos [31] ET and EPT NS NS 4.35(0.05-25)c
Madalinska [34] EPT and tibolone NS (standard) Systemic HT (Oral/transdermal) 3 ± 2.3
Michelsen [35] NS NS Systemic (Oral/transdermal) NS
Rebbeck [20] ET and EPT NS NS NS
Tucker [32] ET NS Systemic HT (20% - oral and transdermal) & local/vaginal HT (8%) NS
  1. HT hormone therapy, ET estrogen therapy, EPT estrogen-progestogen therapy, NS not specified
  2. ain years; bbased on the measure of variance reported in the primary study; caverage duration of use among cases and controls